Supplementary Table S2 from RIG-I–Like Receptor LGP2 Is Required for Tumor Control by Radiotherapy

Wenxin Zheng,Diana Rose E. Ranoa,Xiaona Huang,Yuzhu Hou,Kaiting Yang,Elizabeth C. Poli,Michael A. Beckett,Yang-Xin Fu,Ralph R. Weichselbaum

DOI: https://doi.org/10.1158/0008-5472.22426800

2023-01-01

Abstract:Table S2. Shows Rank Metric Scores for genes for DsRNA response or RIG-I like receptors Signaling

What problem does this paper attempt to address?

Supplementary Table S1 from RIG-I–Like Receptor LGP2 Is Required for Tumor Control by Radiotherapy

Wenxin Zheng,Diana Rose E. Ranoa,Xiaona Huang,Yuzhu Hou,Kaiting Yang,Elizabeth C. Poli,Michael A. Beckett,Yang-Xin Fu,Ralph R. Weichselbaum

DOI: https://doi.org/10.1158/0008-5472.22426803

2023-01-01

Abstract:Table S1. Shows the enrichment scores of gene sets enriched in tumors with high frequency of DCs
RIG-I–Like Receptor LGP2 Is Required for Tumor Control by Radiotherapy

Wenxin Zheng,Diana Rose E Ranoa,Xiaona Huang,Yuzhu Hou,Kaiting Yang,Elizabeth C Poli,Michael A Beckett,Yang-Xin Fu,Ralph R Weichselbaum,Diana Rose E. Ranoa,Elizabeth C. Poli,Michael A. Beckett,Ralph R. Weichselbaum

DOI: https://doi.org/10.1158/0008-5472.can-20-2324

IF: 11.2

2020-10-21

Cancer Research

Abstract:Dendritic cells (DC) play an essential role in innate immunity and radiation-elicited immune responses. LGP2 is a RIG-I-like receptor involved in cytoplasmic RNA recognition and antiviral responses. Although LGP2 has also been linked to cell survival of both tumor cells and T cells, the role of LGP2 in mediating DC function and antitumor immunity elicited by radiotherapy remains unclear. Here, we report that tumor DCs are linked to the clinical outcome of patients with breast cancer who received radiotherapy, and the presence of DC correlates with gene expression of LGP2 in the tumor microenvironment. In preclinical models, host LGP2 was essential for optimal antitumor control by ionizing radiation (IR). The absence of LGP2 in DC dampened type I IFN production and the priming capacity of DC. In the absence of LGP2, MDA5-mediated activation of type I IFN signaling was abrogated. The MDA5/LGP2 agonist high molecular weight poly I:C improved the antitumor effect of IR. This study reveals a previously undefined role of LGP2 in host immunity and provides a new strategy to improve the efficacy of radiotherapy. SIGNIFICANCE: These findings reveal an essential role of LGP2 in promoting antitumor immunity after radiotherapy and provide a new strategy to enhance radiotherapy.

oncology
Supplementary Figures S1 to S6 from RIG-I–Like Receptor LGP2 Is Required for Tumor Control by Radiotherapy

Wenxin Zheng,Diana Rose E. Ranoa,Xiaona Huang,Yuzhu Hou,Kaiting Yang,Elizabeth C. Poli,Michael A. Beckett,Yang-Xin Fu,Ralph R. Weichselbaum

DOI: https://doi.org/10.1158/0008-5472.22426806

2023-01-01

Abstract:Figure S1. describes the apoptotic status of tumor infiltrating and antigen specific CD8+ T cells; Figure S2. describes the apoptotic status and cell surface phenotype of BMDCs; Fig S3. shows an association analysis of LGP2 and overall survival of TNBC and Luminal A patients who received RT; Fig S4. shows correlation analysis between LGP2 expression and clinical outcome of melanoma and sarcoma patients; Figure S5. shows Correlation between gene expression level of LGP2 (DHX58) and signature genes of DCs and CD8+ T cells in human melanoma; Fig S6. shows an association between LGP2 expression and prognosis in pancreatic cancer and colorectal cancers.
Supplementary Table 2 from HDAC Inhibitors Enhance T-Cell Chemokine Expression and Augment Response to PD-1 Immunotherapy in Lung Adenocarcinoma

Hong Zheng,Weipeng Zhao,Cihui Yan,Crystina C. Watson,Michael Massengill,Mengyu Xie,Chris Massengill,David R. Noyes,Gary V. Martinez,Roha Afzal,Zhihua Chen,Xiubao Ren,Scott J. Antonia,Eric B. Haura,Brian Ruffell,Amer A. Beg

DOI: https://doi.org/10.1158/1078-0432.22454714

2023-01-01

Abstract:Supplementary Table 2. Probe sets showing 2-fold difference in expression in 2 independent experiments with romidepsin treatment of LKR. Probe sets with very low expression (cutoff of <100 under all tested conditions) were removed. Probe set ID, direction of change after romidepsin treatment, accession number and gene symbol when available are indicated.
Supplementary Table 2 from MEK Inhibition Modulates Cytokine Response to Mediate Therapeutic Efficacy in Lung Cancer

Mengyu Xie,Hong Zheng,Ranjna Madan-Lala,Wenjie Dai,Nicholas T. Gimbrone,Zhihua Chen,Fumi Kinose,Sarah A. Blackstone,Keiran S.M. Smalley,W. Douglas Cress,Eric B. Haura,Uwe Rix,Amer A. Beg

DOI: https://doi.org/10.1158/0008-5472.22422747

2023-01-01

Abstract:Drug screening data used in Figure 2 are shown, including drug names, cell viability and expression levels of chemokines.
RIG-I–like Receptor LGP2 Protects Tumor Cells from Ionizing Radiation

Ryan C. Widau,Akash D. Parekh,Mark C. Ranck,Daniel W. Golden,Kiran A. Kumar,Ravi F. Sood,Sean P. Pitroda,Zhengkai Liao,Xiaona Huang,Thomas E. Darga,David Xu,Lei Huang,Jorge Andrade,Bernard Roizman,Ralph R. Weichselbaum,Nikolai N. Khodarev

DOI: https://doi.org/10.1073/pnas.1323253111

2014-01-01

Abstract:An siRNA screen targeting 89 IFN stimulated genes in 14 different cancer cell lines pointed to the RIG-I (retinoic acid inducible gene I)-like receptor Laboratory of Genetics and Physiology 2 (LGP2) as playing a key role in conferring tumor cell survival following cytotoxic stress induced by ionizing radiation (IR). Studies on the role of LGP2 revealed the following: (i) Depletion of LGP2 in three cancer cell lines resulted in a significant increase in cell death following IR, (ii) ectopic expression of LGP2 in cells increased resistance to IR, and (iii) IR enhanced LGP2 expression in three cell lines tested. Studies designed to define the mechanism by which LGP2 acts point to its role in regulation of IFNβ. Specifically (i) suppression of LGP2 leads to enhanced IFNβ, (ii) cytotoxic effects following IR correlated with expression of IFNβ inasmuch as inhibition of IFNβ by neutralizing antibody conferred resistance to cell death, and (iii) mouse embryonic fibroblasts from IFN receptor 1 knockout mice are radioresistant compared with wild-type mouse embryonic fibroblasts. The role of LGP2 in cancer may be inferred from cumulative data showing elevated levels of LGP2 in cancer cells are associated with more adverse clinical outcomes. Our results indicate that cytotoxic stress exemplified by IR induces IFNβ and enhances the expression of LGP2. Enhanced expression of LGP2 suppresses the IFN stimulated genes associated with cytotoxic stress by turning off the expression of IFNβ.
Supplementary Table S4 from Receptor-interacting Protein Kinase 2 is an Immunotherapy Target in Pancreatic Cancer

Wenhua Sang,Yiduo Zhou,Haiyan Chen,Chengxuan Yu,Lisi Dai,Zhongkun Liu,Lang Chen,Yimin Fang,Panpan Ma,Xiangji Wu,Hao Kong,Wenting Liao,Hong Jiang,Junbin Qian,Da Wang,Yun-Hua Liu

DOI: https://doi.org/10.1158/2159-8290.25183960

2024-01-01

Abstract:Supplementary Table S4. Primers used for qPCR or generating knockout/knockdown constructs.
Supplementary Table S1 from Receptor-interacting Protein Kinase 2 is an Immunotherapy Target in Pancreatic Cancer

Wenhua Sang,Yiduo Zhou,Haiyan Chen,Chengxuan Yu,Lisi Dai,Zhongkun Liu,Lang Chen,Yimin Fang,Panpan Ma,Xiangji Wu,Hao Kong,Wenting Liao,Hong Jiang,Junbin Qian,Da Wang,Yun-Hua Liu

DOI: https://doi.org/10.1158/2159-8290.25191542

2024-01-01

Abstract:Supplementary Table S1. MAGeCK analysis of CRISPR screen results to identify regulator of immune evasion in orthotopic PDAC mouse models.
Supplementary Table S2 from Receptor-interacting Protein Kinase 2 is an Immunotherapy Target in Pancreatic Cancer

Wenhua Sang,Yiduo Zhou,Haiyan Chen,Chengxuan Yu,Lisi Dai,Zhongkun Liu,Lang Chen,Yimin Fang,Panpan Ma,Xiangji Wu,Hao Kong,Wenting Liao,Hong Jiang,Junbin Qian,Da Wang,Yun-Hua Liu

DOI: https://doi.org/10.1158/2159-8290.25191539

2024-01-01

Abstract:Supplementary Table S2. Detailed information of human pancreatic tissue array.
RASGRP2 is a potential immune-related biomarker and regulates mitochondrial-dependent apoptosis in lung adenocarcinoma

Yongting Liu,Yanhong Ouyang,Ziyang Feng,Zhaohui Jiang,Jiayao Ma,Xin Zhou,Changjing Cai,Ying Han,Shan Zeng,Shanshan Liu,Hong Shen

DOI: https://doi.org/10.3389/fimmu.2023.1100231

IF: 7.3

2023-01-01

Frontiers in Immunology

Abstract:Background: Ras guanine nucleotide-releasing protein 2 (RASGRP2), one of the guanine nucleotide exchange factors (GEFs), has attracted much attention in recent years. However, the correlation between RASGRP2 and immune infiltration and malignant features in lung adenocarcinoma (LUAD) has rarely been mentioned. Methods: The Limma package and the LASSO regression model were performed to screen for differentially expressed genes. Data from the TCGA and 5 GEO databases were used to explore the expression level of RASGRP2 in LUAD patients. A weighted co-expression network and LinkFinder module were established to find the related genes of RASGRP2. The ESTIMATE algorithm was used to analyze the correlation between RASGRP2 and immune infiltration in LUAD. Tumor-infiltrating immune cells were sorted and sequenced at the single-cell level to analyze differences in RASGRP2. Real-time PCR and immunohistochemistry were performed in the real-world cohort to verify the expression of RASGRP2 and its correlation with immune-related genes. Clone formation and EdU assays were used to verify the proliferation ability. The proportion of apoptotic cells was analyzed by flow cytometry. Observation of mitochondrial membrane potential (MMP) changes by fluorescence microscopy. Results: Our results suggested that decreased RASGRP2 was associated with worse clinical parameters and prognosis in LUAD patients. And we constructed a FLI1-HSA-miR-1976-RASGRP2 transcriptional network to support the role of RASGRP2. Enrichment analysis revealed that RASGRP2 was involved in lymphocyte activation and leukocyte adhesion. RASGRP2 was found to be positively correlated with the infiltration of most immune cells, immunoregulators, and chemokines in a subsequent study. Meanwhile, the real-world cohort confirmed that the expression levels of PDCD1, CTLA4, CD40LG, CCL14, CXCR5, and CCR7 were higher in the high-RASGRP2 expression group. Cytological experiments proved that RASGRP2 inhibited cell proliferation in LUAD by regulating mitochondrial-dependent apoptosis. Conclusion: RASGRP2 was a potential immune-related biomarker of LUAD. In addition, RASGRP2 was involved in the malignant progression of LUAD through the regulation of mitochondrial-dependent apoptosis.
Supplementary Table 1 from RAGE Expression in Tumor-Associated Macrophages Promotes Angiogenesis in Glioma

Xuebo Chen,Leying Zhang,Ian Y. Zhang,Junling Liang,Huaqing Wang,Mao Ouyang,Shihua Wu,Anna Carolina Carvalho da Fonseca,Lihong Weng,Yasuhiko Yamamoto,Hiroshi Yamamoto,Rama Natarajan,Behnam Badie

DOI: https://doi.org/10.1158/0008-5472.22402854

2023-01-01

Abstract:Supplementary Table 1: Primers used in the real-time quantitative PCR.
Cancer Therapies Activate Rig-I-Like Receptor Pathway Through Endogenous Non-Coding Rnas

Diana Rose E. Ranoa,Akash D. Parekh,Sean P. Pitroda,Xiaona Huang,Thomas Darga,Anthony C. Wong,Lei Huang,Jorge Andrade,Jonathan P. Staley,Takashi Satoh,Shizuo Akira,Ralph R. Weichselbaum,Nikolai N. Khodarev

DOI: https://doi.org/10.18632/oncotarget.8420

2016-01-01

Oncotarget

Abstract:Emerging evidence indicates that ionizing radiation (IR) and chemotherapy activate Type I interferon (IFN) signaling in tumor and host cells. However, the mechanism of induction is poorly understood. We identified a novel radioprotective role for the DEXH box RNA helicase LGP2 (DHX58) through its suppression of IR-induced cytotoxic IFN-beta [1]. LGP2 inhibits activation of the RIG-I-like receptor (RLR) pathway upon binding of viral RNA to the cytoplasmic sensors RIG-I (DDX58) and MDA5 (IFIH1) and subsequent IFN signaling via the mitochondrial adaptor protein MAVS (IPS1). Here we show that MAVS is necessary for IFN-beta induction and interferon-stimulated gene expression in the response to IR. Suppression of MAVS conferred radioresistance in normal and cancer cells. Germline deletion of RIG-I, but not MDA5, protected mice from death following total body irradiation, while deletion of LGP2 accelerated the death of irradiated animals. In human tumors depletion of RIG-I conferred resistance to IR and different classes of chemotherapy drugs. Mechanistically, IR stimulated the binding of cytoplasmic RIG-I with small endogenous non-coding RNAs (sncRNAs), which triggered IFN-beta activity. We demonstrate that the small nuclear RNAs U1 and U2 translocate to the cytoplasm after IR treatment, thus stimulating the formation of RIG-I: RNA complexes and initiating downstream signaling events. Taken together, these findings suggest that the physiologic responses to radio-/chemo-therapy converge on an antiviral program in recruitment of the RLR pathway by a sncRNA-dependent activation of RIG-I which commences cytotoxic IFN signaling. Importantly, activation of interferon genes by radiation or chemotherapy is associated with a favorable outcome in patients undergoing treatment for cancer. To our knowledge, this is the first demonstration of a cell-intrinsic response to clinically relevant genotoxic treatments mediated by an RNA-dependent mechanism.
The Laboratory of Genetics and Physiology 2: Emerging Insights into the Controversial Functions of This RIG-I-Like Receptor

Zixiang Zhu,Xiangle Zhang,Guoqing Wang,Haixue Zheng

DOI: https://doi.org/10.1155/2014/960190

2014-01-01

BioMed Research International

Abstract:The laboratory of genetics and physiology 2 (LGP2) is a key component of the RNA helicase family of retinoic acid-inducible gene 1- (RIG-I-) like receptors (RLRs) and is widely involved in viral RNA recognition and regulation during innate immune responses. Unlike RIG-I and melanoma differentiation-associated 5, both RLR members, LGP2 lacks the caspase-recruitment domain (CARD), which is required for recruiting and interacting with downstream signaling proteins to activate a cascade of downstream signaling events. The absence of the CARD results in divergent functional performance for LGP2 compared to these other RLR members. Both negative and positive regulatory roles have been reported for LGP2 in antiviral immune responses. It is currently unclear how the unusual properties of LGP2 mediate opposing roles. Future studies should elucidate the molecular mechanism(s) of LGP2 action. This minireview provides a brief overview of LGP2 structure and functions, with an expanded discussion on the regulation mechanisms in response to viral infection, hopefully stimulating insight into the divergent roles of LGP2 in the regulation of antiviral immune responses.
Supplementary Tables 1 and 2, Supplementary Figures 1 Through 25, and Supplementary Methods from Synergistic Immunostimulatory Effects and Therapeutic Benefit of Combined Histone Deacetylase and Bromodomain Inhibition in Non–Small Cell Lung Cancer

Dennis O. Adeegbe,Yan Liu,Patrick H. Lizotte,Yusuke Kamihara,Amir Reza Aref,Christina Almonte,Ruben Dries,Yuyang Li,Shengwu Liu,Xiaoen Wang,Tiquella Warner-Hatten,Jessica A. Castrillon,Guo‐Cheng Yuan,Neermala Poudel-Neupane,Haikuo Zhang,Jennifer L. Guerriero,Song Han,Mark M. Awad,David A. Barbie,Jerome Ritz,Simon Jones,Peter S. Hammerman,James E. Bradner,Steven N. Quayle,Kwok-Kin Wong

DOI: https://doi.org/10.1158/2159-8290.22531702

2023-01-01

Abstract:Supplementary Table 1. HDAC inhibitors tested with healthy donor PBMCs and their biochemical potency (nM) across HDACs 1, 2, 3, and 6. Supplementary Table 2. Information for consented Non-small cell lung cancer (NSCLC) patients that underwent surgical resectioning as part of their treatment plan and whose tumor specimen and blood samples obtained after surgery were analyzed. Supplementary Figure 1. Reduced CD4+FOXP3+ Treg cells in healthy donor and NSCLC patient PBMC in the presence of ricolinostat. Supplementary Figure 2. Up-regulation of CD69 on T cells in healthy donor PBMC cultures in the presence of ricolinostat. Supplementary Figure 3. Viability of immune cells within dissociated tumor specimens cultured in the presence of ricolinostat or entinostat. Supplementary Figure 4. Effector function of T cells within 2-D cultures of disaggregated tumor specimens from NSCLC patients. Supplementary Figure 5. Increased expression of MHC class II and CD86 on monocytes in healthy donor PBMC in the presence of ricolinostat. Supplementary Figure 6. Phenotype of T cells infiltrating lung tumors of genetically engineered mice treated with ricolinostat. Supplementary Figure 7. Gene expression profile of Tumor-infiltrating T cells. Supplementary Figure 8. Ricolinostat promotes up-regulation of MHC class II and CD86 on tumor-associated macrophages. Supplementary figure 9. Immunohistochemical and flow cytometric analyses of acetylated α-tubulin in lung tumors of KP mice. Supplementary Figure 10. Kinetics of tumor growth in KP mice treated with ricolinostat. Supplementary Figure 11. Phenotype of tumor-infiltrating T cell subsets in lung tumors of KP mice treated with JQ1. Supplementary Figure 12. Immunohistochemical and flow cytometric analyses of phospho-STAT5 levels in lung tumors of KP mice. Supplementary Figure 13. Suppressive function of Tregs isolated from the spleen of lung tumor-bearing KP mice treated with JQ1. Supplementary Figure 14. Phenotype of Tregs in the spleen or lung tumors of genetically engineered mouse models (GEMM) of NSCLC. Supplementary Figure 15. Phenotype of Tregs within cultures of dissociated tumor specimen from NSCLC patients. Supplementary Figure 17. Histology and immunohistochemical staining of lung tumor sections from treated KP mice. Supplementary Figure 18. Kinetics of tumor growth in TL or wild-type mice. Supplementary Figure 19. Quantification of T cell subsets and TAMs in tumors of KP mice. Supplementary Figure 20. Phenotype of CD8+T cells infiltrating lung tumors of treated KP mice. Supplementary Figure 21. Gene expression profile of tumor-infiltrating macrophages (TAMs) in treated KP mice. Supplementary Figure 22. Gene expression profile of tumor-infiltrating macrophages T cells in treated KP mice. Supplementary Figure 23. Proportion of CD4+Foxp3+ Tregs present within tumor-infiltrating T cells utilized in gene expression studies. Supplementary Figure 24. Gating strategy. Supplementary Figure 25. Correlation plot for the expression of indicated genes in CD45+ leukocytes in KP tumors as evaluated by single cell RNA-Sequencing.
Multiomics Differences in Lung Squamous Cell Carcinoma Patients with High Radiosensitivity Index Compared with Those with Low Radiosensitivity Index

Yajing Du,Sujuan Yuan,Xibing Zhuang,Qi Zhang,Tiankui Qiao

DOI: https://doi.org/10.1155/2021/3766659

2021-01-01

Disease Markers

Abstract:Objectives. Radiosensitivity Index (RSI) can predict intrinsic radiotherapy sensitivity. We analyzed multiomics characteristics in lung squamous cell carcinoma between high and low RSI groups, which may help understand the underlying molecular mechanism of radiosensitivity and guide optional treatment for patients in the future. Methods. The Cancer Genome Atlas (TCGA) and the Gene Expression Omnibus (GEO) data were used to download clinical data, mRNA, microRNA, and lncRNA expression. Differential analyses, including mRNA, miRNA, lncRNA, and G.O. and KEGG, and GSVA analyses, were performed with R. Gene set enrichment analysis was done by GSEA. miRNA-differentially expressed gene network and ceRNA network were analyzed and graphed by the Cytoscape software. Results. In TCGA data, 542 patients were obtained, including 171 in the low RSI group (LRSI) and 371 in the high RSI group (HRSI). In RNAseq, 558 significantly differentially expressed genes (DEGs) were obtained. KRT6A was the most significantly upregulated gene and IDO1 was the most significantly downregulated gene. In miRNAseq, miR-1269a was the most significantly upregulated. In lncRNAseq, LINC01871 was the most upregulated. A 66-pair interaction between differentially expressed genes and miRNAs and an 11-pair interaction between differential lncRNAs and miRNAs consisted of a ceRNA network, of which miR-184 and miR-490-3p were located in the center. In the GEO data, there were 40 DEGs. A total of 17 genes were founded in both databases, such as ADAM23, AHNAK2, BST2, COL11A1, CXCL13, FBN2, IFI27, IFI44L, MAGEA6, and PTGR1. GSVA analysis revealed 31 significant pathways. GSEA found 87 gene sets enriched in HRSI and 91 gene sets in LRSI. G.O. and KEGG of RNA expression levels revealed that these genes were most enriched in T cell activation and cytokine−cytokine receptor interaction. Conclusions. Patients with lung squamous cell carcinoma have different multiomics characteristics between two groups. These differences may have an essential significance with radiotherapy effect.
Supplementary Table 2 from Ribonucleotide Reductase Small Subunit M2B Prognoses Better Survival in Colorectal Cancer

Xiyong Liu,Lily Lai,Xiaochen Wang,Lijun Xue,Sofia Leora,Jun Wu,Shuya Hu,Keqiang Zhang,Mei-Ling Kuo,Lun Zhou,Hang Zhang,Yafan Wang,Yan Wang,Bingsen Zhou,Rebecca A. Nelson,Shu Zheng,Suzhan Zhang,Peiguo Chu,Yun Yen

DOI: https://doi.org/10.1158/0008-5472.22393487.v1

2023-01-01

Abstract:Supplementary Table 2 from Ribonucleotide Reductase Small Subunit M2B Prognoses Better Survival in Colorectal Cancer
Supplementary Table S5 from CD38-Mediated Immunosuppression As a Mechanism of Tumor Cell Escape from PD-1/PD-L1 Blockade

Limo Chen,Lixia Diao,Yongyi Yang,Xiaohui Yi,B. Leticia Rodriguez,Yanli Li,Pamela Villalobos,Tina Cascone,Xi Liu,Tao Lin,Philip L. Lorenzi,Anfei Huang,Qiang Zhang,Di Peng,Jared J. Fradette,David H. Peng,Christin Ungewiss,Jonathon D. Roybal,Pan Tong,Junna Oba,Ferdinandos Skoulidis,Weiyi Peng,Brett W. Carter,Carl M. Gay,Fan Yu,Caleb A. Class,Jianxin Zhu,Jaime Rodriguez‐Canales,Masanori Kawakami,Lauren A. Byers,Scott E. Woodman,Vassiliki A. Papadimitrakopoulou,Ethan Dmitrovsky,Jing Wang,Stephen E. Ullrich,Ignacio I. Wistuba,John V. Heymach,F. Xiao-Feng Qin,Don L. Gibbons

DOI: https://doi.org/10.1158/2159-8290.22532336.v1

2023-01-01

Abstract:The ranked gene list for GSEA.
Supplementary Table S2 from CD24hiCD27+ Bregs Within Metastatic Lymph Nodes Promote Multidrug Resistance in Breast Cancer

Huanhuan Huang,Yao,Lesang Shen,Jingxin Jiang,Ting Zhang,Jia Xiong,Jiaxin Li,Shanshan Sun,Siwei Zheng,Fang Jia,Jun Zhou,Xiuyan Yu,Wuzhen Chen,Jun Shen,Wenjie Xia,Xuan Shao,Qingqing Wang,Jian Huang,Chao Ni

DOI: https://doi.org/10.1158/1078-0432.24826125.v1

2023-01-01

Abstract:Table. S2. Annotation of the 92 Olink biomarkers studied herein.
Supplementary Table S2 from Cables1 Complex Couples Survival Signaling to the Cell Death Machinery

Zhi Shi,Hae R. Park,Yuhong Du,Zijian Li,Kejun Cheng,Shi-Yong Sun,Zenggang Li,Haian Fu,Fadlo R. Khuri

DOI: https://doi.org/10.1158/0008-5472.22404699

2023-01-01

Abstract:Supplementary Table S2. Human lung tumor sample histology information and IHC scoring summary.
Additional File 14: Table S4. of Measure Transcript Integrity Using RNA-seq Data

Liguo Wang,Jinfu Nie,Hugues Sicotte,Ying Liu,Jeanette E. Eckel‐Passow,Surendra Dasari,Peter T. Vedell,Poulami Barman,Liewei Wang,Richard Weinshiboum,Jin Jen,Haojie Huang,Manish Kohli,Jean-Pierre Kocher

DOI: https://doi.org/10.6084/m9.figshare.c.3611075_d11

2016-01-01

Abstract:List of 10 low RIN/medTIN mCRPC and 10 higher RIN/medTIN mCRPC samples used for differential expression analysis. “N” = Metastatic bone site, “V1” = Visit 1. Whole datasets are available with accession # GSM1722952. (XLS 97 kb)

Supplementary Table S2 from RIG-I–Like Receptor LGP2 Is Required for Tumor Control by Radiotherapy

Supplementary Table S1 from RIG-I–Like Receptor LGP2 Is Required for Tumor Control by Radiotherapy

RIG-I–Like Receptor LGP2 Is Required for Tumor Control by Radiotherapy

Supplementary Figures S1 to S6 from RIG-I–Like Receptor LGP2 Is Required for Tumor Control by Radiotherapy

Supplementary Table 2 from HDAC Inhibitors Enhance T-Cell Chemokine Expression and Augment Response to PD-1 Immunotherapy in Lung Adenocarcinoma

Supplementary Table 2 from MEK Inhibition Modulates Cytokine Response to Mediate Therapeutic Efficacy in Lung Cancer

RIG-I–like Receptor LGP2 Protects Tumor Cells from Ionizing Radiation

Supplementary Table S4 from Receptor-interacting Protein Kinase 2 is an Immunotherapy Target in Pancreatic Cancer

Supplementary Table S1 from Receptor-interacting Protein Kinase 2 is an Immunotherapy Target in Pancreatic Cancer

Supplementary Table S2 from Receptor-interacting Protein Kinase 2 is an Immunotherapy Target in Pancreatic Cancer

RASGRP2 is a potential immune-related biomarker and regulates mitochondrial-dependent apoptosis in lung adenocarcinoma

Supplementary Table 1 from RAGE Expression in Tumor-Associated Macrophages Promotes Angiogenesis in Glioma

Cancer Therapies Activate Rig-I-Like Receptor Pathway Through Endogenous Non-Coding Rnas

The Laboratory of Genetics and Physiology 2: Emerging Insights into the Controversial Functions of This RIG-I-Like Receptor

Supplementary Tables 1 and 2, Supplementary Figures 1 Through 25, and Supplementary Methods from Synergistic Immunostimulatory Effects and Therapeutic Benefit of Combined Histone Deacetylase and Bromodomain Inhibition in Non–Small Cell Lung Cancer

Multiomics Differences in Lung Squamous Cell Carcinoma Patients with High Radiosensitivity Index Compared with Those with Low Radiosensitivity Index

Supplementary Table 2 from Ribonucleotide Reductase Small Subunit M2B Prognoses Better Survival in Colorectal Cancer

Supplementary Table S5 from CD38-Mediated Immunosuppression As a Mechanism of Tumor Cell Escape from PD-1/PD-L1 Blockade

Supplementary Table S2 from CD24hiCD27+ Bregs Within Metastatic Lymph Nodes Promote Multidrug Resistance in Breast Cancer

Supplementary Table S2 from Cables1 Complex Couples Survival Signaling to the Cell Death Machinery

Additional File 14: Table S4. of Measure Transcript Integrity Using RNA-seq Data